Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
123
CIMA_AEMPS:81
SFDA:23
EMA:15
+1 more agencies
Drug Approvals
Etelcalcetide Hydrochloride Injection
- Product Name
- 旁必福
- Approval Number
- 国药准字HJ20230046
- Approval Date
- May 6, 2023
NMPA
Etelcalcetide Hydrochloride Injection
- Product Name
- 旁必福
- Approval Number
- 国药准字HJ20230047
- Approval Date
- May 6, 2023
NMPA
Etelcalcetide Hydrochloride Injection
- Product Name
- 旁必福
- Approval Number
- 国药准字HJ20230048
- Approval Date
- May 6, 2023
NMPA
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)No trials found
News
EMA Recommends Approval of Tepezza for Thyroid Eye Disease, First Targeted Treatment in EU
The European Medicines Agency has recommended approval of Tepezza (teprotumumab) for adults with moderate to severe thyroid eye disease, marking the first targeted therapy for this condition in the EU.